Stephen V Liu, Associate Professor of Medicine at Georgetown University, shared a post on X:

“NEOADAURA results published in JCO after ASCO 2025 presentation.

In patients with resectable EGFR-Mutated NSCLC, neoadjuvant osimertinib for 9 weeks led to MPR rate of 25%, osimertinib + chemotherapy MPR 26%, and placebo + chemotherapy MPR of 2%. EFS rates high, but most patients received adjuvant osimertinib.”

Title: Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer

Journal: Journal of Clinical Oncology

Authors: Jianxing He, Masahiro Tsuboi, Walter Weder, Ke-Neng Chen, Maximilian J. Hochmair, Jin-Yuan Shih, Sung Yong Lee, Kang-Yun Lee, Nguyen Viet Nhung, Somcharoen Saeteng, Lunxu Liu, Ligang Xing, Nguyen Hoang Gia, Shuji Murakami, Yongtao Han, María Paz Saavedra, Seong Hoon Yoon, Carlos H.A. Teixeira, Carles Escriu, Alex Martinez-Marti, Collin M. Blakely, Yasushi Yatabe, Sanja Dacic, Yuri Rukazenkov, Xiangning Huang, Anupriya Dayal, Jamie E. Chaft

Read the full abstract.

NEOADAURA

More posts featuring Stephen V Liu on OncoDaily.

Stephen V Liu Shared NEOADAURA Results Published in JCO After ASCO25 Presentation

“NEOADAURA results published in JCO after ASCO 2025 presentation.

In patients with resectable EGFR-Mutated NSCLC, neoadjuvant osimertinib for 9 weeks led to MPR rate of 25%, osimertinib + chemotherapy MPR 26%, and placebo + chemotherapy MPR of 2%. EFS rates high, but most patients received adjuvant osimertinib.”